Unlocking therapeutic potential IL-1β as a target in non-small cell lung cancer with oncogenic mutations – prognostic and predictive insights


Won Jin Jeon, Mengni Guo, Alexander Gavralidis, Bowon Joung, Andrew Elliott, Yasmine Baca, Mark Reeves, Saied Mirshahidi, Ari Vanderwalde, Hamid Mirshahidi


  • Heterogeneity in interleukin-1β (IL-1β) expression in nonsmall cell lung cancer (NSCLC) samples has been observed
  • Despite the incidental finding of improved lung cancer incidence and mortality with the IL-1β inhibitor canakinumab, clinical trials such as CANOPY 1 and 2 failed to show improved outcomes with chemo/immunotherapy
  • The clinical implications and interplay of oncogenic driver mutations and IL-1β in the setting of varying treatment modalities including immune-checkpoint inhibitors (ICIs) have not been previously explored
  • The aim of this study is to evaluate the prognostic and predictive role of IL-1β in NSCLC with respect to driver mutations such as KRAS, EGFR, ERBB2, BRAF, STK11, and ALK fusion
Download Publication